Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816613 | 0.81 | SMN1; SMN2 (0.42) | LMNAALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9482070 | 0.79 | ALDH1A1 (0.56) | LMNAALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6294536 | 0.76 | MAOB (0.50) | LMNAALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL941193 | 0.76 | GLA (0.42) | LMNAALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1144143 | 0.75 | MCHR1 (0.44) | SMN1; SMN2KDM4ETDP1PTGDR2 | |
| SCHEMBL1447864 | 0.72 | SLC6A4 (0.59) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL30504080 | 0.72 | SLC6A4 (0.59) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL6449279 | 0.72 | CCR5 (0.52) | LMNAALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL23925228 | 0.71 | TSHR (0.41) | LMNASMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL21493114 | 0.69 | KDM5A (0.35) | LMNAKDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166746-B2 | N-bisaryl- and n-aryl-cycloakylidenyl-αhydroxy-and α-alkoxy acid amides | SYNGENTA CROP PROTECTION, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050245607-A1 | N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides | SYNGENTA CROP PROTECTION, INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1534664-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | Syngenta Participations AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-20040214721-A1 | Novel n-bisaryl- and n-aryl-cycloalkylidenyl-alpha-sulfin- and alpha-sulfonamino acid amides | SYNGENTA CROP PROTECTION, INC. | 2004-10-28 | — | — | US | disclosed |
| EP-1399418-A1 | NOVEL N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-$G(a)-SULFIN- AND $G(a)-SULFONAMINO ACID AMIDES | Syngenta Participations AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004011417-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003002525-A1 | NOVEL N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-$G(a)-SULFIN- AND $G(a)-SULFONAMINO ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214721-A1 | Novel n-bisaryl- and n-aryl-cycloalkylidenyl-alpha-sulfin- and alpha-sulfonamino acid amides | ARSA, SFN, HCCS | LMNA 1330/4885ALDH1A1 1061/4885SMN1; SMN2 1279/4885 |
| US-20050245607-A1 | N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides | CBR3, CBR1, AKR1C3 | LMNA 1315/4885ALDH1A1 1049/4885SMN1; SMN2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.